Literature DB >> 6193516

Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon.

B D Williamson, E A Carswell, B Y Rubin, J S Prendergast, L J Old.   

Abstract

Human cell lines of hematopoietic origin were tested for production of tumor necrosis factor (TNF). B-cell lines transformed by Epstein-Barr virus release a factor (referred to as hTNF) that is cytotoxic for mouse L cells sensitive to mouse TNF but not for L cells resistant to mouse TNF. Exposure to 4 beta-phorbol 12 beta-myristate 13 alpha-acetate augmented production of hTNF. hTNF activity was not found in supernatants of cell lines of T-cell, monocytic, or promyelocytic origin. Partially purified hTNF has a molecular weight of approximately 70,000, has no interferon activity, is acid labile, is destroyed by heating at 70 degrees C for 1 hr, induces cross-resistance to mouse TNF in vitro, and causes hemorrhagic necrosis of Meth A mouse sarcoma in the standard in vivo mouse TNF assay. Tests with a panel of 23 human cancer cell lines showed that hTNF is cytotoxic for 7 cell lines, cytostatic for 5, and has no effect on 11. Comparative studies with human alpha, beta, and gamma interferons indicated that sensitivity to hTNF and interferon can be distinguished. Combined treatment with hTNF and alpha or gamma interferon resulted in a synergistic cytotoxic effect.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193516      PMCID: PMC384263          DOI: 10.1073/pnas.80.17.5397

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Effect of tumour necrosis factor on cultured human melanoma cells.

Authors:  L Helson; S Green; E Carswell; L J Old
Journal:  Nature       Date:  1975-12-25       Impact factor: 49.962

2.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

3.  Macrophages as a source of tumoricidal activity (tumor-necrotizing factor).

Authors:  D N Männel; R N Moore; S E Mergenhagen
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

Review 4.  Lymphotoxin: properties, role and mode of action.

Authors:  W Rosenau
Journal:  Int J Immunopharmacol       Date:  1981

5.  Preliminary characterization of the tumor cell cytotoxin in tumor necrosis serum.

Authors:  F C Kull; P Cuatrecasas
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

6.  Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells.

Authors:  E C Borden; T F Hogan; J G Voelkel
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

7.  Partial purification of a serum factor that causes necrosis of tumors.

Authors:  S Green; A Dobrjansky; E A Carswell; R L Kassel; L J Old; N Fiore; M K Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1976-02       Impact factor: 11.205

8.  Interferon induced in human leukocytes by mitogens: production, partial purification and characterization.

Authors:  M de Ley; J van Damme; H Claeys; H Weening; J W Heine; A Billiau; C Vermylen; P de Somer
Journal:  Eur J Immunol       Date:  1980-11       Impact factor: 5.532

9.  Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents.

Authors:  B Y Rubin; S L Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

10.  Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro.

Authors:  K Haranaka; N Satomi
Journal:  Jpn J Exp Med       Date:  1981-06
View more
  112 in total

Review 1.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

2.  Determination of tumor necrosis factor in blister fluids of bullous pemphigoid.

Authors:  H Takematsu; H Ohta; H Tagami
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

3.  Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.

Authors:  L Liu; W Li; Z Li; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

4.  A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.

Authors:  Daniel R Jones
Journal:  Ann Transl Med       Date:  2015-08

5.  Recombinant human tumour necrosis factor (rTNF)2 enhances leukotriene biosynthesis in neutrophils and eosinophils stimulated with the Ca2+ ionophore A23187.

Authors:  R Roubin; P P Elsas; W Fiers; A J Dessein
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

6.  Tumor necrosis factor expression in human epithelial tumor cell lines.

Authors:  D R Spriggs; K Imamura; C Rodriguez; E Sariban; D W Kufe
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

7.  Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo.

Authors:  R Beyaert; B Vanhaesebroeck; P Suffys; F Van Roy; W Fiers
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

8.  Tumour necrosis factor in synovial exudates.

Authors:  F S Di Giovine; G Nuki; G W Duff
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

9.  Macrophage functions in Biozzi mice.

Authors:  H M Dockrell; J Taverne; R Lelchuk; P Depledge; I N Brown; J H Playfair
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

10.  Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2.

Authors:  G A Limb; A Meager; J Woolley; M Wadhwa; J Biggerstaff; K A Brown; R A Wolstencroft
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.